亚太传统医药2026，Vol.22Issue(3)：34-40,7.DOI:10.11954/ytctyy.202603007
清痰通络方治疗慢性阻塞性肺疾病急性加重期痰瘀阻肺证临床疗效观察
Study on the Clinical Efficacy of Qingtan Tongluo Formula in the Treatment of Phlegm Stasis Obstructing Lung Syndrome in Acute Exacerbation of Chronic Obstructive Pulmonary Disease
摘要
Abstract
Objective:To evaluate the clinical efficacy of Qingtan Tongluo Formula combined with conventional Western medicine therapy for treating patients with acute exacerbation of chronic obstructive pulmonary disease(AECOPD)presenting with the syndrome of phlegm stasis obstructing the lung.Additionally,to assess its modulatory effects on in-flammation and coagulation parameters.Methods:80 AECOPD patients diagnosed with the phlegm stasis obstructing the lung syndrome were enrolled from Jinjiang Hospital between July 2024 and July 2025.Participants were equally al-located into either a Chinese medicine(CM)group or a control group using a random number table.The control group received standardized Western medical treatment alone.The CM group received identical Western medical treatment and adjunctive therapy with Qingtan Tongluo Formula for 7 consecutive days.Comparisons were made between the two groups regarding:(1)Clinical efficacy rate;(2)Traditional Chinese medicine(TCM)syndrome scores(specifically for wheezing and fever);(3)Complete blood count parameters and derived inflammatory indices:Neutrophil(NEU),Lymphocyte(LYM),Monocyte(MONO)counts,Neutrophil-to-Lymphocyte Ratio(NLR),and Systemic Inflamma-tion Response Index(SIRI);(4)Serum inflammatory markers:C-reactive Protein(CRP)and Procalcitonin(PCT);and(5)Coagulation function markers:Fibrinogen(FIB)and D-Dimer(D-D).Results:The effective treatment rate of the TCM group was 95%,which was significantly higher than that of the control group(80%)(P<0.05;relative risk[RR]=1.19,95%confidence interval[CI]=[1.03,1.37]).After treatment,the TCM group demonstrated superior improvements in wheezing(P=0.001,95%CI=[0.69,0.89]),fever(P=0.016,95%CI=[0.81,0.98]),and to-tal TCM syndrome score(P=0.002,95%CI=[0.71,0.95])compared to the control group(all P<0.05).Regard-ing immune-related indices,the TCM group showed a more significant increase in lymphocyte count(LYM)(P=0.039,95%CI=[1.01,1.25]),and greater reductions in neutrophil-to-lymphocyte ratio(NLR)(P=0.021,95%CI=[0.73,0.97])and systemic inflammation response index(SIRI)(P=0.036,95%CI=[0.74,0.99])than the con-trol group(all P<0.05).Additionally,the TCM group exhibited more pronounced improvements in inflammatory markers,including C-reactive protein(CRP)(P=0.013,95%CI=[0.85,1.11]),procalcitonin(PCT)(P=0.005,95%CI=[0.71,0.95]),and coagulation function indicator fibrinogen(FIB)(P=0.004,95%CI=[0.72,0.96]),when compared to the control group(all P<0.05).Conclusion:Qingtan Tongluo Formula combined with conventional Western medicine demonstrates favorable clinical efficacy in treating AECOPD patients with the phlegm-blood stasis obstruc-ting the lung syndrome.This integrated approach significantly alleviates clinical symptoms,mitigates the systemic inflammato-ry response,and improves coagulation function.It is,therefore,worthy of clinical promotion and broader application.关键词
慢性阻塞性肺疾病急性加重期/清痰通络方/痰瘀阻肺/名老中医经验Key words
Acute Exacerbation of Chronic Obstructive Pulmonary Disease/Qingtan Tongluo Formula/Phlegm Stasis Obstructing the Lungs/Experience of Renowned Traditional Chinese Medicine Practitioners分类
医药卫生引用本文复制引用
蔡志胜,余晓红,郭杏仁,吴志平,陈悦,沈志勇,郭为汀..清痰通络方治疗慢性阻塞性肺疾病急性加重期痰瘀阻肺证临床疗效观察[J].亚太传统医药,2026,22(3):34-40,7.基金项目
全国名老中医药专家传承工作室建设项目(国中医药人教函[2022]75号) （国中医药人教函[2022]75号）
福建省名老中医药专家传承工作室建设项目(闽卫中医[2018]216号) （闽卫中医[2018]216号）
福建中医药大学校管课题临床专项(XB2024212) （XB2024212）
